Cell-Cycle Dysregulation

1. The Cell Cycle in Outline

The eukaryotic cell cycle is the ordered, irreversible sequence of events by which one cell becomes two: duplicate the genome, segregate it accurately, divide. In a typical proliferating mammalian cell with a 24 h cycle, the four canonical phases are traversed in roughly:

• G1 (~11 h) — growth, mitogen integration, commitment decision at the restriction point.
• S (~8 h) — DNA replication; ~3×10⁹ bp copied with <1 error per genome.
• G2 (~4 h) — preparation for mitosis, checkpoint surveillance for replication completion and damage.
• M (~1 h) — mitosis: prophase → prometaphase → metaphase → anaphase → telophase, then cytokinesis.
• G0 — reversible quiescence; most cells in an adult body live here.

The cycle is unidirectional. Each transition is driven by an oscillating cyclin-dependent kinase (CDK) activity and locked in by ubiquitin-mediated proteolysis of the previous cyclin. Hartwell, Hunt and Nurse received the 2001 Nobel Prize for identifying the genetic and biochemical basis of this engine; Hartwell from yeast cdc mutants, Hunt from sea-urchin egg cyclins, Nurse from fission-yeast cdc2 (CDK1).

For background on the underlying physiology, see the cell-physiology cell-cycle module.

2. CDKs and Cyclins — the Engine

The cell cycle is driven by sequentially activated heterodimers of a constitutively expressed catalytic subunit — a cyclin-dependent kinase (CDK) — bound to a periodically expressed regulatory subunit, a cyclin. Cyclin binding rotates the C-helix and re-orders the activation loop; phosphorylation of a conserved threonine (Thr160 in CDK2) by CAK (CDK7–cyclin H) completes activation. Inhibitory phosphorylation at Tyr15 (and Thr14 in CDK1) by Wee1/Myt1 holds activity off until CDC25 phosphatases remove it.

The minimal recognition logic: cyclin binds the N-terminal lobe and unwinds the PSTAIRE helix; the ATP-binding cleft and the substrate-binding pocket open. Many CDK substrates are docked through a hydrophobic patch (HP) on the cyclin, which recognises an RxL motif in the substrate (Rb, E2F1, p27, p21 all carry RxL).

\[ \text{Cyclin} + \text{CDK} \xrightarrow{\;\text{CAK / pT160}\;} \text{active}_{\text{Wee1-pY15}} \xrightarrow{\;\text{CDC25}\;} \text{active CDK} \]

3. The Restriction Point and the Rb–E2F Switch

The molecular substrate of the restriction point is the retinoblastoma protein (Rb / pRB / RB1), the prototypical “pocket protein” (with p107, p130). In its hypophosphorylated active state, Rb binds and represses the E2F family of transcription factors that drive expression of S-phase genes (cyclin E, cyclin A, CDC6, CDC25A, dihydrofolate reductase, thymidylate synthase, MCM2–7, PCNA, >100 targets).

The switch — in three steps

1. Mitogens → cyclin D. Growth-factor signalling (Ras→Raf→MEK→ERK; PI3K→mTOR) induces cyclin D transcription and stabilises the protein.
2. Cyclin D–CDK4/6 mono-phosphorylates Rb. A single Rb residue is phosphorylated at a time (Sanidas et al., Mol Cell 2019); this partial inactivation releases some E2Fs.
3. Cyclin E–CDK2 hyper-phosphorylates Rb. Once cyclin E is induced, it forms a positive-feedback loop with E2F: hyper-phosphorylated Rb releases E2F fully, more cyclin E is transcribed, the cell crosses R irreversibly.

\[ \text{Rb}_{\text{hypo}}\!\cdot\!\text{E2F} \xrightarrow{\;\text{cycD-CDK4/6}\;} \text{Rb}_{\text{mono-P}} \xrightarrow{\;\text{cycE-CDK2}\;} \text{Rb}_{\text{hyper-P}} + \text{E2F}\!\uparrow \]

The Rb–E2F bistable switch was modelled as an explicit dynamical system by Yao, Lee, Nevins & You (Nat Cell Biol 2008): a serum-pulse experiment showed an all-or-none cellular memory of past mitogen exposure encoded by E2F levels. The Rb pathway is functionally inactivated in essentially every cancer — by RB1 loss, CDKN2A loss, cyclin D amplification, or HPV E7 sequestration of Rb. Hanahan & Weinberg list “sustaining proliferative signalling” and “evading growth suppressors” as two of the original six hallmarks (Cell 2000, 2011).

4. The DNA-Damage Checkpoints

When DNA damage is detected, cells halt the cycle to allow repair. The three damage checkpoints are anatomically distinct — they act at different cycle positions and use partially different machinery — but they share the apical kinase pair ATM (responding to double-strand breaks) and ATR (responding to single-stranded DNA and stalled forks). ATM and ATR are PIKK-family Ser/Thr kinases.

At the apex sits p53. Stabilised by ATM/ATR phosphorylation (Ser15, Ser20, Ser46) and by p14^ARF (which sequesters MDM2), p53 transactivates CDKN1A (p21), BAX, PUMA, GADD45, 14-3-3σ, MDM2 (negative feedback), and more than 100 other targets. The decision between cycle arrest, senescence, and apoptosis depends on damage dose, cell type, and on which co-factors (e.g. ASPP1/2, iASPP) tune p53 toward specific promoters. p53 is mutated in >50% of all human tumours.

\[ \text{DSB} \;\to\; \text{ATM} \;\to\; \text{CHK2} \;\to\; \text{p53} \;\to\; \text{p21} \;\dashv\; \text{cycE-CDK2} \;\Rightarrow\; \text{G1 arrest} \]

\[ \text{ssDNA / stalled fork} \;\to\; \text{ATR} \;\to\; \text{CHK1} \;\to\; \text{CDC25A/C ubiq.} \;\Rightarrow\; \text{S/G2 arrest} \]

5. The Spindle-Assembly Checkpoint

Mitotic chromosome segregation is monitored by the spindle-assembly checkpoint (SAC), discovered in genetic screens by Hoyt and Murray (1991) as the mad (mitotic-arrest deficient) and bub (budding uninhibited by benomyl) genes. Each kinetochore that has not yet captured spindle microtubules biamphitelically generates a wait-anaphase signal: the mitotic checkpoint complex (MCC), comprising Mad2, BubR1, Bub3 and Cdc20.

The MCC sequesters Cdc20 and prevents it from activating the anaphase-promoting complex/cyclosome (APC/C), the E3 ligase that ubiquitinates securin and cyclin B. With securin intact, separase is inhibited, sister-chromatid cohesion (held by cohesin's Scc1 ring) is preserved, and anaphase cannot start. As soon as the last kinetochore makes correct end-on attachment, the MCC dissolves; APC/C-Cdc20 fires; securin and cyclin B are degraded; separase cleaves Scc1; the chromatids fly apart on shrinking microtubules.

\[ \text{unattached KT} \to \text{MCC (Mad2-Cdc20-BubR1-Bub3)} \dashv \text{APC/C} \;\Rightarrow\; \text{securin}\!\uparrow,\;\text{cyc B}\!\uparrow,\;\text{anaphase blocked} \]

Aurora B at the inner centromere phosphorylates incorrect (syntelic, merotelic) attachments to release them. This error correction is mechanistically coupled to SAC signalling through Mps1, which licenses both Mad1/Mad2 recruitment and Aurora-B-dependent destabilisation. Pharmacological probes: nocodazole and Taxol (paclitaxel, used clinically) trap cells in mitosis with active SAC; the SAC eventually “slips” over hours, producing tetraploid G1 cells that frequently die.

6. CDK Inhibitors — the Natural Brakes

Two structurally distinct families of endogenous inhibitor proteins (CKIs) restrain CDKs:

p27^Kip1 is regulated post-translationally: in quiescent cells it is high; mitogen signalling triggers its phosphorylation by cyclin E–CDK2 at Thr187, recognition by SCF^Skp2, ubiquitination, and degradation. Loss of p27 is prognostic in breast cancer. CDKN2A loss (the INK4a/ARF locus) is one of the most frequent genetic events in cancer: a single deletion eliminates both p16^INK4a and the alternative-reading-frame p14^ARF tumour suppressor.

7. Cell-Cycle Defects in Cancer

The Rb pathway is functionally inactivated in essentially every malignancy. The hits are interchangeable at the pathway level but have distinct genetic signatures and therapeutic implications:

These lesions are mutually exclusive at the pathway level: tumours with CDKN2A loss almost never carry CCND1 amplification, and vice versa — both achieve the same effect (cyclin D–CDK4/6 hyperactivity). This pathway-level exclusivity is one of the strongest computational signatures of functional epistasis in cancer genomics (Mina et al. Cancer Cell 2017).

8. Replication Stress as a Tumour Driver

Replication stress — the slowing, stalling, or collapse of replication forks — is now recognised as a near-universal feature of pre-cancerous and cancerous cells. Bartkova, Halazonetis and colleagues (Nature 2005, 2006) showed that benign and early-stage neoplastic lesions already exhibit DNA-damage response (γH2AX, 53BP1, ATM-pS1981) markers, indicating that oncogene-induced replication stress is one of the earliest detectable tumourigenic events. p53 is then selected to be lost because it would otherwise enforce senescence or apoptosis in response.

Mechanisms by which oncogenes cause replication stress

• Premature S-phase entry — cyclin E hyperactivity (CCNE1 amp) shortens G1, depletes the dNTP pool, and de-licences origins.
• Increased origin firing — MYC, RAS over-expression force aberrant origin usage; many fire close together and collapse.
• Transcription–replication conflicts — deregulated transcription (R-loops) collides with forks; common-fragile-site instability follows.
• Nucleotide-pool imbalance — oncogene-driven proliferation outpaces dNTP supply, slowing forks.
• Re-replication — loss of geminin or hyperactive CDC6 can fire origins more than once per cycle.

The cellular response to replication stress is the ATR–CHK1 axis: RPA-coated ssDNA at stalled forks recruits ATRIP/ATR; the 9-1-1 clamp recruits TopBP1 (and ETAA1) to activate ATR; ATR phosphorylates CHK1, stabilising forks (FANCD2, BLM, BRCA1/2), suppressing late origin firing (CDC25A degradation), and pausing the cycle.

\[ \text{stalled fork} \to \text{RPA-ssDNA} \to \text{ATR} \to \text{CHK1} \;\Rightarrow\; \text{fork stabilisation, origin suppression, S/G2 arrest} \]

Cancers thus live with chronically elevated replication stress — but they also suppress the responses that would otherwise kill them (p53 loss). This creates a therapeutic window: drugs that worsen replication stress or that disable the residual ATR/CHK1 response selectively kill cancer cells.

9. CDK4/6 Inhibitors in the Clinic

The single most successful translation of cell-cycle biology into oncology has been the development of selective CDK4/6 inhibitors for hormone-receptor-positive (HR+), HER2-negative metastatic breast cancer. The biological rationale: HR+ breast cancers depend on oestrogen-driven cyclin D1 transcription → CDK4/6 activity → Rb phosphorylation. Combined with endocrine therapy, CDK4/6 inhibition produces durable Rb-dependent cell-cycle arrest.

All three are oral, ATP-competitive, and selective for CDK4 and CDK6 over CDK1/2/9 (palbociclib IC₅₀: CDK4 ~10 nM, CDK6 ~15 nM, CDK2 >10 μM). Common toxicities reflect on-target inhibition of bone-marrow CDK6 (neutropenia, especially with palbociclib and ribociclib) and gut effects (diarrhoea, particularly abemaciclib). Ribociclib carries a QTc-prolongation warning.

Resistance mechanisms

• RB1 loss — the canonical resistance mechanism; cells no longer need CDK4/6 to inactivate Rb.
• Cyclin E1/E2 over-expression — CDK2 bypass of CDK4/6.
• FAT1, AURKA, FGFR1 alterations — emergent in plasma genotyping (Wander et al. Cancer Discov 2020).
• PI3K/AKT/mTOR reactivation — restores cyclin D translation; rationale for triplet combinations with alpelisib or everolimus.
• ESR1 mutations — ligand-independent ER activation; addressed by oral SERDs (elacestrant).

10. Therapeutic Implications Beyond CDK4/6

The cell-cycle machinery offers many more therapeutic opportunities. Most exploit synthetic lethality: cancer-specific defects (replication stress, p53 loss, MYC over-expression) make tumour cells more dependent on a residual checkpoint or repair pathway than normal cells.

A unifying principle. Cancers proliferate because they have broken the cell-cycle controls that normal cells use. They survive because they have also disabled the apoptotic responses that would otherwise execute cells with broken cycles. This double break is what creates therapeutic vulnerability: a cancer that has lost p53 cannot mount a G1 arrest, so its only remaining defence against replication stress is the G2/M ATR–CHK1–Wee1 axis — and that axis is now drugged. Part IV will examine the DNA-repair pathways whose loss creates the analogous opportunity for PARP inhibitors and platinum agents.